StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the stock.
TherapeuticsMD Price Performance
NASDAQ TXMD opened at $1.58 on Wednesday. TherapeuticsMD has a 12 month low of $1.43 and a 12 month high of $3.07. The stock’s fifty day moving average price is $1.70 and its 200-day moving average price is $1.85.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.
Institutional Investors Weigh In On TherapeuticsMD
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- Stock Analyst Ratings and Canadian Analyst Ratings
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Use the MarketBeat Excel Dividend Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- The 3 Best Fintech Stocks to Buy Now
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.